Company intelligence / Profile preview

Regeneration Biomedical, Inc.

Newport Beach, California, United Statesregenerationbiomedical.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Phase 1 clinical trial data on the first cohort of Alzheimer's patients showed RB-ADSCs were well tolerated, reduced levels of p-Tau and amyloid-beta at 12 weeks, and improved Mini-Mental State Examination (MMSE) scores in two of three subjects[7]

Therapeutic areas: Neurology
Modalities: Autologous stem cell therapy
Industry: Biotech

Drug pipeline

1 asset

RB-ADSC-03

Unknown

Beyond the preview

Go deeper on Regeneration Biomedical, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Regeneration Biomedical, Inc..

Explore the full profile